Papers
2020 – Targeting Nuclear LSD1 to Reprogram Cancer Cells and Reinvigorate Exhausted T Cells via Novel LSD1-EOMES Switch
2020 – Epitherapy and immune checkpoint blockade: using epigenetic reinvigoration of exhausted and dysfunctional T cells to reimburse immunotherapy response
2019 – Immune modulation via epigenetic targeting to overcome immune checkpoint inhibitor resistance
2016 – Identification of chromatin accessibility domains in human breast cancer stem cells
There is a substantial unmet clinical need when it comes to fighting recurrent, metastatic breast cancer. This is the major cause of death in women with breast cancer. We aim to address that unmet need by the novel targeting of breast cancer stem cells, which are resistant to conventional systemic anticancer therapies and therefore contribute to the failure of these therapies in patients.
Professor Sudha Rao
Founder at EpiAxis Therapeutics